Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Ovulation Detection”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,279 records · Page 71Linked to original sources
PubMed1994

Evaluation of transvaginal sonography combined with a urinary luteinizing hormone monitor in timing donor insemination.

There remains controversy as to the most accurate method of predicting ovulation for the timing of donor insemination. In a prospective study based at a tertiary referral donor insemination clinic we have assessed the ability of a urinary luteinizing hormone (LH) kit combined with vaginal ultrasonography to predict ovulation for donor insemination. A total of 25 natural cycles were monitored from the first day of the LH surge (detected by the urinary kit). Daily transvaginal sonographic measurement of follicular size and endometrial thickness were used to predict ovulation; monitoring continued until post-ovulatory changes were seen. Transvaginal sonography combined with a urinary LH kit successfully predicted all those women who ovulated (20/25) and detected unfavourable conditions for insemination in the remaining 20% (5/25). In conclusion, where available transvaginal sonography combined with a urinary LH kit should be the method of choice for timing donor insemination.

Endometrium↗
PubMed2002

Effects of dose and route of administration of cloprostenol on luteolysis, estrus and ovulation in beef heifers.

Four experiments were conducted (with crossbred beef heifers) to determine the effects of dose and route of administration of cloprostenol on luteolysis, estrus and ovulation. In Experiment 1, 19 heifers with a CL > or = 17 mm in diameter were randomly allocated to receive cloprostenol as follows: 100 microg s.c., 250 microg s.c., or 500 microg i.m. Heifers given 100 microg s.c. had a longer (P<0.03) interval (120.0 h+/-10.7 h; mean+/-S.E.M.) from treatment to ovulation than those given either 250 microg s.c. or 500 microg i.m. (92.0 h+/-7.4 h and 84.0 h+/-8.2 h, respectively). In Experiment 2, 28 heifers were given porcine LH (pLH), followed in 7 days by cloprostenol (same doses and routes as in Experiment 1), and a second dose of pLH 48 h after cloprostenol. Luteolysis occurred in all heifers, and no difference was detected among treatment groups in the interval from cloprostenol treatment to ovulation (mean, 101 h; P<0.9). In Experiment 3, 38 heifers at random stages of the estrous cycle (but with plasma progesterone concentrations > or =1.0 ng/ml) received 500 or 125 microg cloprostenol by either i.m. or s.c. injection (2/2 factorial design). There was no difference (P<0.4) among groups in the proportions of heifers that were detected in estrus or that ovulated. However, the interval from cloprostenol treatment to estrus was shorter (P<0.02) in the group that received 500 microg i.m. (58.5h) than in the other three groups (500 microg s.c., 75.0 h; 125 microg i.m., 78.0 h; and 125 microg s.c., 82.3h). In Experiment 4, 36 heifers were treated (as in Experiment 3) on Day 7 after ovulation. The proportions of heifers detected in estrus and ovulating after 125 microg s.c. (33 and 44%, respectively) or 125 microg i.m. (55 and 55%) were lower (P<0.05) than in those that received 500 microg s.c. (100 and 100%), but not different from those receiving 500 microg i.m. (78 and 89%, respectively). Overall, ovulation was detected in 9/18 heifers given 125 microg and 17/18 heifers given 500 microg of cloprostenol, on Day 7 (P<0.01) and was detected in 17/20 heifers given 125 microg and 18/18 heifers given 500 microg of cloprostenol, at random stages of the estrous cycle (P>0.05). Although there was no significant difference in luteolytic efficacy between i.m. and s.c. injections of the recommended dose (500 microg) of cloprostenol, variability in responsiveness to a reduced dose depended upon CL sensitivity, therefore, reduced doses cannot be recommended for routine use.

Animals↗
PubMed1996

Time of ovulation relative to mounting activity in dairy cattle.

Time of ovulation was determined for Holstein cows (n = 51) for estruses occurring spontaneously (n = 33) or those induced by PGF2 alpha (n = 86). Ultrasound examination of ovaries was conducted 42 to 49 d postpartum, followed by administration of 25 mg of PGF2 alpha if a corpus luteum was observed. In the absence of a corpus luteum, ovaries were reexamined weekly, and PGF2 alpha was administered upon observation of the presence of a corpus luteum. Onset of estrus was determined by HeatWatch, an electronic pressure-sensing system that recorded each mount associated with estrus. To determine ovulation in relation to first detected mount, ultrasound examinations were conducted at 12, 20, and 24 h after the initial mount and then every 2 h until 40 h. Cows were assigned randomly to receive one of two treatments: 1) the cow received 25 mg of PGF2 alpha 8 to 13 d later or 2) the cow was allowed to cycle spontaneously and then was switched to alternate treatment at a third cycle. The mean estrus period, determined from mounting activity recorded by HeatWatch, consisted of 10.1 mounts over 9.5 h (6.0 mounts were > or = 2 s) for a total 24.1 s of mounting activity. Estrus characteristics were extremely variable and were not different for estruses induced by PGF2 alpha or for those occurring spontaneously. Mean ovulation time relative to first mount was 27.6 +/- 5.4 h and was not different between spontaneous and induced estruses. Knowing the time of ovulation in reference to the first mount of estrus and being able to identify the first mount consistently and accurately with the HeatWatch system allows for accurate timing of AI.

Animals↗
PubMed1996

Home ovulation testing in a donor insemination service.

The use of home ovulation testing kits in donor insemination (DI) has been proposed to increase patient and clinic convenience while not compromising fecundity rates. Such a system was introduced into our DI service in December 1994, and we here report an audit of experience over 6 months. Patients were offered home or laboratory luteinizing hormone (LH) testing, and those requesting home testing were asked to store an aliquot of tested urine for subsequent assay in the laboratory allowing retrospective analysis of the accuracy of cycle timing. Insemination using cryopreserved semen was performed on the day home testing predicted ovulation, or on the day an LH surge was detected in the laboratory, and on the following day. Pregnancy rates were significantly reduced in home testers: 3.4% per cycle (174 cycles, 64 women) versus 12.7% (110 cycles, 53 women) over the same time period (P < 0.005, 95% confidence interval 6.5-18.9). Urine samples from 140 cycles from 51 women using home testing were analysed. There were insufficient data in nine to allocate the cycle. Of home tested cycles, 37 (28%) were inseminated on a day other than the first day of the LH surge. In 13 of these insemination was performed after the first day of the LH surge. Incorrect treatment was associated with high baseline LH, but those with 'late' treatment had low basal LH concentrations, similar to those correctly treated. Analysis of individual urine samples showed that the positive predictive value of home testing was 72%. These results suggest that home ovulation testing results in reduced chance of pregnancy, with increased frustration for both patients and clinic staff. This may be particularly so in women with high baseline LH concentrations.

Adult↗
PubMed1981

[Evolution of plasma levels of glycoproteic gonadotropins and of 17 alpha hydroxy-20 beta dihydroprogesterone during maturation and ovulation of rainbow trout, Salmo gairdnerii].

The plasma concentrations of the glycoproteic gonadotropin (GTH) and of the 17 alpha hydroxy-20 beta dihydroprogesterone (17 alpha 20 beta OHP) have been followed in the course of ovulation in 6 rainbow trout, using radioimmunoassays on samples taken every two days. A first slow and limited GTH increase (10 to 20 ng/ml) is detected before and during the ovulation, while the 17 alpha 20 beta OHP rises sharply (up to three to five hundreds nanogrammes per millilitre). Then the progestagen levels drop back to their previous values, for about three weeks after ovulation. At the same time, a second higher GTH increase (25 to 20 ng/ml) is taking place. The relations between these two hormones, maturation and ovulation are discussed.

Animals↗
PubMed2003

Relationship between endotoxin and prostaglandin (PGE2 and PGFM) concentrations and ovarian function in dairy cows with puerperal endometritis.

Blood concentrations of progesterone, 13,14-dihydro-15-keto-prostaglandin F2alpha (PGFM) and endotoxin, and uterine fluid concentrations of prostaglandin E(2) (PGE(2)), PGFM and endotoxin were evaluated in 14 dairy cows with puerperal endometritis (mild (n=6) and heavy (n=8)). Endotoxin was measured using a quantitative kinetic assay. Cows with heavy endometritis had significantly higher concentrations of plasma PGFM (P<0.01) and uterine fluid PGE(2) and endotoxin (P<0.05) than cows with mild endometritis. Concentrations of PGFM in plasma and uterine fluid, of PGFM and PGE(2), and PGE(2) and endotoxin in uterine fluid were positively and significantly (P<0.05) correlated. The presence of endotoxin in plasma was detected in one out of six mild and in eight out of eight heavy endometritis cows. Peak plasma endotoxin concentrations (0.08-9.14 endotoxin units/ml (EU/ml) were observed between 1 and 12 days postpartum (pp) and thereafter amounts generally remained below 0.1 EU/ml (last day of detection: Day 27 pp). Abnormal ovarian function was observed in six cows (four with prolonged anoestrus and two with long luteal phase after the first postpartum ovulation). Plasma endotoxin concentrations were detected in the anoestric cows. The results suggest that: (i) concentrations of uterine fluid endotoxin and PGE(2) and of plasma PGFM are related to the degree of endometritis; (ii) absorption of endotoxin from the uterus to the bloodstream occurs, mainly in heavy endometritis cows; and (iii) there is a relationship between uterine infection, endotoxin production and resumption of pp ovarian activity.

Animals↗
PubMed1990

Immunohistochemical localization of growth hormone-releasing hormone in human gonads.

Human gonads were examined for the presence of ir growth hormone-releasing-hormone. We demonstrated the presence of immunostainable cells both in ovarian and in testicular tissue using a non-crossreactive anti-GRH antiserum and the immunoperoxidase detection technique. In ovaries from ovulating women, GRH immunoreactivity was localized in the corpora lutea; granulosa cells, theca cells and cells of primary follicles did not stain. In premenopausal ovaries, staining was detectable in scattered luteinized stromal cells. In testes from post-puberal men GRH immunoreactivity was localized in the Leydig cells; cells of the germinal epithelium did not stain. These results demonstrate the presence of GRH in human gonads and suggest that this peptide may exert regulatory function at the testicular and ovarian levels.

Female↗
PubMed1988

Murine ovulatory response to ultrasound exposure and its gynecological relevance.

Ultrasonographic assessment of ovarian follicular maturity was reportedly associated with atypically early ovulation in women; related studies reported reduced litter sizes in rats. To confirm these findings, mice which were midway between ovulatory gonadotropin (LH or human chorionic gonadotropin) stimulation and ovulation, were sham- or ultrasound-treated periovarially for 5 min. Exposure was at a spatial average, temporal maximum intensity of 60 W/cm2. Carrier frequency in the pulse was 2.2 MHz, pulse length was 10 microseconds, and pulse repetition frequency was 200 Hz. Spatial average, temporal average intensity was 0.12 W/cm2. At autopsy, ultrasound- and sham-treated groups responded similarly in proportions ovulating and in mean ova ovulated. Combined experiments had a 97% chance of detecting a significant (greater than 1 h) advance in ovulation time, had it occurred. Thus, our adequately sensitive mammalian ovulatory tests revealed no association of ultrasound with decrease in ovum number or acceleration in ovulation time (as reported in humans).

Animals↗
PubMed1990

Methods of ovulation induction.

The results of ovulation induction in patients with ovulatory dysfunction were reviewed for a one year period. Eighty-six women were assigned to four groups: secondary amenorrhea, anovulation, oligo-ovulation, and luteal phase defect/short luteal phase (LPD). All patients were monitored with basal body temperature (BBT) graph, postcoital testing, and ultrasonic scanning of ovarian follicles. All patients received therapy with clomiphene citrate (CC) for a minimum of four cycles and 13 patients conceived. Fifty patients were offered additional therapy with human menopausal gonadotropins (HMG-HCG). Seventeen completed a minimum of four cycles, and 13 conceived. The number of CC-treated patients with poor mucus quality in the face of adequate follicular development was 24, or 48%. The overwhelming problem with ovulation induction when CC failed was the large number of patients who dropped out of therapy, 48%. In summary, close monitoring during ovulation induction to confirm ovulation, and assess mucus quality and luteal function allow detection and correction of inadequate response. Induction of ovulation can be highly successful if patients can follow through and complete protocols of therapy.

Adult↗
PubMed1975

Steroid levels in follicles and the plasma of hens during the ovulatory cycle.

Laying hens were killed at hourly intervals during the 26-h laying cycle. The 3 largest follicles of the size hierarchy were removed and plasma samples were obtained from the same hens. The follicle walls and the plasma were assayed by RIA for estrogen (E), progesterone (P4), and testosterone (T). The data show that for E and T there is an inverse relationship between follicle size and hormone concentration. There is no such difference for P4. Both E and T show a significant drop immediately after ovulation; P4 does not. Both T and E concentrations rise significantly and synchronously at about 4 and at 8 h after ovulation. The OAAD assay of plasma shows a peak of LH about that time. P4 does not show such a rise in concentration. About 8 to 10 h prior to the next ovulation T concentration in all 3 follicles begins to rise, P4 rises only in the largest follicle and E only in the smallest. All three steroids reach highly significant peaks about 4 to 6 h prior to the next ovulation. Both OAAD and RIA detect plasma LH peaks at about that time. Plasma E and follicle E peak synchronously at 4 to 8 h; T peaks occur at 10 to 12 h after ovulation and are asynchronous with the T follicle peaks. All 3 steroids begin to rise in the plasma about 10 h prior to the next ovulation and all 3 peak together about 4 to 5 h prior to ovulation. The present data do not allow to distinguish between rates of steroid synthesis and their release into the plasma. Whether the steroid peaks occurring in both follicles and plasma shortly before the next ovulation are caused by LH or are the cause of its release remains to be determined.

Animals↗
PubMed1977

Specific and sensitive determination of pregnancy-specific beta 1-glycoprotein by radioimmunoassay. A new pregnancy test.

A specific and highly sensitive radioimmunoassay (R.I.A.) for determination of pregnancy-specific beta 1-glycoprotein (S.P.1) in human plasma, urine, amniotic fluid, and breast milk has been developed. The minimum detection limit of S.P.1 was 8 mug/1 of sample. The assay was applied to plasma and/or urine samples from 8 women in early pregnancy. S.P. 1 was detected in the plasma of all three women obtained within 14 days of ovulation, the earliest positive result being at 7 days. In another woman plasma was negative at day 18 and positive by day 22. In the three remaining women plasma S.P.1 was detected when measured within 24 to 36 days of ovulation. S.P.1 was detected in four urine samples obtained between 20 and 28 days after ovulation. S.P.1 was also measured in breast milk, amniotic fluid, cord blood, and plasma of women with ectopic gestation and trophoblastic disease. It is suggested that the assay of S.P.1 may have important advantages over existing systems for detection and monitoring of early pregnancy.

Amniotic Fluid↗
PubMed2001

Effects of hormonal treatments on reproductive performance and embryo production.

Developments in the use of drugs to improve reproduction and embryo production have focused on estrus and ovulation synchronization protocols and embryonic survival. Protocols for synchronization of ovulation eliminate the need for detection of estrus and allow timed insemination of all cows enrolled. Various estrogenic, progestational, GnRH and PGF2 alpha-like drugs are used to synchronize follicle development, CL regression and induction of ovulation. Strategies are discussed to optimize such programs to maximize herd pregnancy rates. Use of bovine Somatotrophin (bST) in combination with the Ovsynch protocol resulted in increased pregnancy rates, indicating possible effects on oocyte and embryonic development. Treatment of embryo donor cows with bST reduced the proportion of unfertilized oocytes and increased the number of transferable embryos. Furthermore, bST increased pregnancy rate when given to the recipient. Sub-luteal plasma progesterone concentrations after insemination have been associated with lower pregnancy rates. Injection of hCG on day 5 post-insemination resulted in induction of an accessory CL, increased plasma progesterone concentrations and increased conception rates. Strategies involving the use of sustained GnRH agonists to enhance CL development and alter follicular development are considered for future programs to enhance pregnancy rates.

Animals↗
PubMed1995

Serial measurement of peripheral oestrogen and progesterone concentrations in oestrous mares to determine optimum mating time and diagnose ovulation.

Rapid enzyme-based immunoassays were used to measure concentrations of oestradiol-17 beta and progesterone in daily blood samples recovered throughout oestrus and for a few days after ovulation from 34 Thoroughbred and 8 pony-type maiden, barren and foaling mares. The first detectable fall in oestradiol-17 beta levels occurred in 88% of the mares within the interval -72 to 0 h with respect to ovulation and in 65% of mares within the interval of -48 to 0 h. The results indicated that serial daily hormone assays of this type could, in a high proportion of animals, predict a correct time for a single mating and diagnose the occurrence of ovulation in Thoroughbred mares at stud in the absence of the present management system which includes repeated veterinary examinations of the ovaries. However, the absolute need for serial daily sampling from all mares to produce interpretable hormone profiles, and the cost of this sampling and the hormone assays, make the method impractical at the present time.

Animals↗
PubMed1994

Resumption of follicular activity and interval to postpartum ovulation after exogenous progestins.

In Experiment 1, treatment of dairy cows with progesterone using an intravaginal device from d 5 to 15 postpartum failed to alter onset or duration of the first estrous cycle. Compared with controls in Experiment 2, concentrations of FSH increased, and those of LH decreased, in cows treated with either norgestomet or progesterone for 6 d. Relationships of various measures of LH, but not FSH, were all positive with increasing days postpartum, and those of FSH produced positive polynomial regressions as days to first ovulation decreased. No significant changes in follicular status occurred during or after progestin treatments; however, a consistent relationship was observed between increasing diameter of dominant follicles and serum concentrations of estradiol-17 beta in most cows. Appearance of the ovulatory dominant follicle generally was detected 4 to 5 d before ovulation regardless of treatment and was first detected more frequently during treatment with progestins when concentrations of FSH were increased compared with controls. Concentrations of progesterone were higher on d 7 to 10 following removal of progestin treatments. Appearance of the first dominant follicle was detected during periods of increased average minimum concentrations of FSH, increased variation in LH secretion, and was related to subsequent duration of the first estrous cycle.

Animals↗
PubMed1984

[Ovulation prediction in cattle by rapid measurement of plasma LH and by laparoscopic observation].

The last hours of intrafollicular maturation are important to preserve the potential of oocytes for fertilization and development. To collect mature oocytes it is consequently essential to predict accurately the time of ovulation. Therefore we have modified a regular and specific plasma LH radioimmunoassay to a convenient assay providing reliable results within four to five hours. Using this technique we have been able to detect the LH peak with a delay small enough to predict the moment of ovulation; then we have been able to observe and photograph ovulation. The antigen-antibody reaction takes place during a two hour incubation at 37 degrees C. The immune complex is precipitated by addition of a rabbit anti-gamma-globulin and incubation at 22 degrees C for 30 minutes. The variation between fast and regular assays is lower than 15%. From a study of 25 cycles in 12 animals we suggest intervals of approximately 27 hours between the beginning of the LH peak and ovulation and of about 17 hours between the end of the peak and ovulation. Intervals between the beginning of heat and ovulation appear irregular and cannot be used with certainty as a reference point to predict ovulation. Five ovulations were observed closely and in the five cases, the formation of an apex was noted Our results clearly show that with the technique mentioned above we can predict rapidly and precisely bovine ovulation.

Animals↗
PubMed1997

Anti-implantation activity of luteal phase mifepristone administration is not mimicked by prostaglandin synthesis inhibitor or prostaglandin analogue in the rhesus monkey.

The use of mifepristone as an anti-implantation agent in the primate has been explored in the rhesus monkey with two specific aims: (i) to determine the contraceptive efficacy of very low-dose mifepristone administered on mated cycle days 16, 17, and 18; and (ii) to test the hypothesis that alteration in endometrial prostaglandin milieu by using either prostaglandin analogue or prostaglandin synthesis inhibitor can intervene the antifertility effect induced by mifepristone. Thirty female monkeys were randomly assigned to one of the six treatment groups. Five monkeys in the control group (group 1) were subjected to mating during cycle days 8-22. Four out of five monkeys became pregnant in the first mated cycle (80%) with detection of serum mCG by 12.7 +/- 1.5 days after ovulation. In group 2, 12 mated cycles were studied in five monkeys, mifepristone [RU486, 2 mg/day/animal, s.c. in 1 ml vehicle (1:4, benzyl benzoate:olive oil, v/v)] was given on cycle days 16, 17, and 18. In this group, no pregnancy was observed, thus providing complete pregnancy protection. Though there was an apparent extension of treatment cycle lengths in five cases with no incidence of inter-menstrual bleeding or spotting, there were no significant changes in serum estradiol (E) and progesterone (P). In group 3, four monkeys received prostaglandin (PG) synthesis inhibitor, diclofenac sodium (D, 25 mg/day/animal, i.m.) on cycle days 16, 17, and 18 in seven ovulatory menstrual cycles. Four of these cycles (57%) resulted in normal pregnancies; however, mCG detection (16.8 +/- 1.2 days after ovulation) was significantly (p < 0.05) delayed as compared to group 1. In group 4, four monkeys received 100 micrograms misoprostol (M), a PGE1 analogue, by gavage on mated cycle days 16, 17, and 18. Four pregnancies occurred in five treatment cycles (80%) with normal profiles of serum E and Pi mCG was first detected 13.2 +/- 1.7 days after ovulation. In group 5, seven monkeys received same dosages of RU486 and D on mated cycle days 16, 17, and 18. One hundred percent pregnancy protection was observed with luteal phase lengthening in eight treatment cycles but with unaltered E and P profiles. In group 6, five monkeys in nine treatment cycles received same dosages of RU486 and M on mated cycle days 16, 17, and 18. One pregnancy occurred; evaluation of E and P levels showed that the drug was given in the preovulatory period, which delayed ovulation and implantation, as mCG was detected 19 days post-ovulation. A delay in vaginal bleeding was observed in four treatment cycles with unaltered E and P profiles. Low-dose mifepristone appears to be a potential candidate for luteal phase and post-coital emergency contraception. However, the hypothesis that altered endometrial prostaglandin milieu may be responsible for mediating the anti-implantation effect of RU486 does not appear to be tenable based on our results in the rhesus monkey.

Abortifacient Agents, Steroidal↗
PubMed2001

Short-term treatment with a controlled internal drug releasing (CIDR) device and FSH to induce fertile estrus and increase prolificacy in anestrous ewes.

The objectives were to evaluate, in anestrous ewes, the effectiveness of a CIDR-G device (0.3 g progesterone) administered for 5 d to induce estrus; and FSH (Folltropin; 55 mg NIH-FSH-P1 equivalent) in saline:propylene glycol (1:4) 24 h before insert removal (Day 0), to increase ovulation rate and prolificacy. Ewes of mixed breeding were assigned at random to 3 treatments: control (C; n = 125), 5 d progesterone (P5; n = 257) and 5 d progesterone plus FSH (P5F; n = 271). Intact rams were joined at insert removal and ewes were observed every 24 h for 3 d. On Day 14, the ovulation rates of all ewes detected in estrus in the treated groups were determined using transrectal ultrasonography. Rams were removed on Day 26 to 31. Ewes were examined for pregnancy then, and again 20 to 25 d later to detect ewes that conceived to the second service period. Percentage of ewes marked by rams was higher in progesterone-treated (77%) than in C (20%; P < 0.01), but did not differ between P5 and P5F. The ovulation rate (1.95+/-0.04) did not differ due to FSH. Conception (68%) and pregnancy (52%) rates were higher in progesterone-treated (P < 0.01) than in C (0%) ewes. Estrous response varied quadratically with time after ram introduction, and the conception rate varied quadratically with the time of observation of onset of estrus. Over two service periods more progesterone-treated than C ewes lambed (65 vs 45%; P < 0.01). Lambs born per ewe exposed (0.7+/-0.1, 1.0+/-0.1, and 1.1+/-0.1 for C, P5 and P5F, respectively) was increased by progesterone (P < 0.05). Litter size to the first service period (1.59+/-0.04) and overall (1.54+/-0.03) did not differ among treatment groups. FSH-treated ewes tended to have more lambs (1.67+/-0.1) than did ewes receiving progesterone alone (1.5+/-0.1; P = 0.06) and than did ewes lambing to the second service period (1.5+/-0.1; P = 0.06). In summary, a 5-d progesterone pre-treatment of anestrous ewes induced estrous cycles and increased the pregnancy rates. A single injection of FSH only tended to increase litter size.

Animals↗
PubMed1990

Ultrasonic morphology of corpora lutea and central luteal cavities during the estrous cycle and early pregnancy in heifers.

Ultrasonography was used once daily to quantify corpora lutea, central luteal cavities, and luteinized tissue during interovulatory intervals (n=66) and during Days 0 to 60 of pregnancy (n=14) in nulliparous Holstein heifers (ovulation=Day 0). The corpus luteum of the estrous cycle was detectable by ultrasonography in most heifers from the day of ovulation (mean, Day 0.5) and extending into the regressive phase beyond the next ovulation (mean, Day 1.4+/-0.2 after the next ovulation). During pregnancy, the corpus luteum was detected until Day 60 (end of study). Maximal central luteal cavity area detected on Days 0 to 20 was used retrospectively to group luteal glands into four cavity categories: no, small, medium, and large. These categories corresponded to approximate cavity diameters of <2 mm, 2 to 5 mm, 6 to 10 mm, and >10 mm, respectively. The incidence of each cavity category was similar between interovulatory intervals and pregnancies (combined incidence, 17/80, 8/80, 33/80, and 22/80 for no, small, medium, and large cavities, respectively; total with cavities, 63/80, 79%). Mean day of first detection of a central cavity was earliest for large cavities during interovulatory intervals (means, Days 4.7, 4.4, and 3.0 for small, medium, and large cavities, respectively; P<0.04) and during pregnancies (means, Days 5.5, 4.2, and 3.3, respectively; NS). However, the day that the cavities reached maximum size (range of means, Days 5.5 to 7.0) did not differ among categories. Mean day of last detection of the central cavity was significantly different among cavity categories during interovulatory intervals (means, Days 9.3, 11.1, and 17.4 for small, medium, and large cavities, respectively) and pregnancies (means, Days 7.0, 8.8, and 20.2, respectively). Time of loss of central cavities was similar between nonbred and pregnant heifers, and there was no significant difference among cavity categories in the length of the interovulatory interval (mean, 20.1 d). Luteal tissue area was not significantly different among cavity categories during interovulatory intervals. There were no indications that cavities were functionally important. Luteal tissue area increased linearly in pregnant heifers on Days 21 to 60 (mean slope, 2.6 mm2/day).

Journal Article↗